Harvey Capital Management INC Decreased Stake in Nektar Therapeutics (NKTR) by $7.55 Million as Shares Rose

April 16, 2018 - By Michele Cranor

Nektar Therapeutics (NASDAQ:NKTR) Corporate LogoBig Money Sentiment decreased to 1.19 in 2017 Q4. It has change of 0.21, from 2017Q3’s 1.4. The ratio worsened due to NKTR positioning: 18 sold and 82 reduced. 65 funds bought positions and 54 increased positions. Investors holded 148.76 million in 2017Q3 but now own 150.36 million shares or 1.08% more. Brinker Cap Incorporated accumulated 20,557 shs. Adage Prns Gru Llc holds 0.02% or 139,000 shs in its capital. Profund Lc holds 0.19% of its capital in Nektar Therapeutics (NASDAQ:NKTR) for 80,937 shs. Bancorporation Of Montreal Can reported 0% stake. Teacher Retirement System Of Texas holds 0.02% of its capital in Nektar Therapeutics (NASDAQ:NKTR) for 53,545 shs. Jpmorgan Chase And owns 1.61 million shs for 0.02% of their capital. Pointstate Lp has 3.93 million shs for 2.28% of their capital. Westfield Cap Mngmt LP has invested 1.05% in Nektar Therapeutics (NASDAQ:NKTR). Vident Invest Advisory Lc has 21,339 shs for 0.07% of their capital. Advisory Svcs Networks Ltd Liability Corp reported 0% of its capital in Nektar Therapeutics (NASDAQ:NKTR). Morgan Stanley owns 749,353 shs for 0.01% of their capital. Polar Llp reported 1.02M shs. Guggenheim Capital Ltd Llc holds 0.02% in Nektar Therapeutics (NASDAQ:NKTR) or 151,055 shs. Kazazian Asset Llc has invested 1.19% in Nektar Therapeutics (NASDAQ:NKTR). 138,464 were accumulated by Dimensional Fund Advisors Lp.

NKTR had 17 selling transactions and 0 insider purchases since December 13, 2017. This’s net activity of $66.98 million. Hora Maninder also sold $53,046 worth of Nektar Therapeutics (NASDAQ:NKTR) on Tuesday, April 10. GREER R SCOTT had sold 30,000 shs worth $2.77 million on Friday, April 6. On Tuesday, March 6 Shares for $21.85 million were sold by Nicholson John. $2.30M worth of Nektar Therapeutics (NASDAQ:NKTR) was sold by CHESS ROBERT. 2,545 Nektar Therapeutics (NASDAQ:NKTR) shs with value of $211,082 were sold by Thomsen Jillian B.. On Friday, February 16 $288,382 worth of stock was sold by Labrucherie Gil M.

Based on the latest 2017Q4 regulatory filing with the SEC, Harvey Capital Management Inc reduced its holdings in Nektar Therapeutics (NKTR) by 44.53%. 127,890 shares were sold by Harvey Capital Management Inc as the company’s stock rose 80.22% while stock markets declined. At the end of 2017Q4, the 159,310 shares of the major pharmaceuticals company held by the institutional investor were valued at $9.51 million, down from 287,200 at the end of the previous reported quarter. For a total of 82,535 shares it increased its holding in Time Warner Inc New (NYSE:TWX) by 66,035 shares in the quarter, and has risen its stake in Verizon Communications (NYSE:VZ).

Analysts await Nektar Therapeutics (NASDAQ:NKTR) to report earnings on May, 8. They expect $-0.43 earnings per share, down 2.38 % or $0.01 from last year’s $-0.42 per share. After $-0.14 actual earnings per share reported by Nektar Therapeutics for the previous quarter, Wall Street now forecasts 207.14 % negative EPS growth.

Nektar Therapeutics (NASDAQ:NKTR) Ratings Coverage

Total analysts of 7 have positions in Nektar Therapeutics (NASDAQ:NKTR) as follows: 7 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since October 18, 2017 according to StockzIntelligence Inc Nektar Therapeutics has 12 analyst reports. On Friday, April 13 the firm has “Overweight” rating given by PiperJaffray. The stock rating was maintained by Canaccord Genuity with “Buy” on Wednesday, January 10. On Friday, April 6 Mizuho maintained Nektar Therapeutics (NASDAQ:NKTR) rating. Mizuho has “Buy” rating and $10300 target. On Monday, November 13 the rating was maintained by Roth Capital with “Buy”. The stock rating was reinitiated by H.C. Wainwright with “Buy” on Monday, April 2. On Wednesday, October 18 the company was maintained by Jefferies. On Thursday, November 9 Canaccord Genuity initiated Nektar Therapeutics (NASDAQ:NKTR) with “Buy” rating. On Wednesday, November 8 the company was maintained by Jefferies. On Thursday, March 29 Mizuho maintained the shares of NKTR in report with “Buy” rating. The company rating was maintained by Cowen & Co on Monday, April 9.

Nektar Therapeutics (NASDAQ:NKTR) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: